NCT01992016View on ClinicalTrials.gov

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 7, 2014

Primary Completion Date

October 8, 2016

Study Completion Date

April 11, 2018

Conditions
Adenocarcinoma of the ProstateBone MetastasesSoft Tissue MetastasesStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

Ranolazine

1000mg given orally twice daily for 1 day (2 doses).

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT01992016 - A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine | Biotech Hunter | Biotech Hunter